PTIX — Protagenic Therapeutics Income Statement
0.000.00%
- $4.01m
- $1.59m
- 22
- 15
- 45
- 17
Annual income statement for Protagenic Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 2.09 | 2.55 | 4.14 | 3.56 | 4.53 |
Operating Profit | -2.09 | -2.55 | -4.14 | -3.56 | -4.53 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -1.75 | -2.55 | -4.52 | -3.56 | -5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.75 | -2.55 | -4.52 | -3.56 | -5 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.75 | -2.55 | -4.52 | -3.56 | -5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.75 | -2.55 | -4.52 | -3.56 | -5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.683 | -0.986 | -1.23 | -0.823 | -1.15 |